(MENAFN- GlobeNewsWire - Nasdaq) itemprop="articleBody">Herantis Pharma Plc's financial reporting schedule and annual general meeting in 2019
Herantis Pharma Plc.
Company release 18 December 2018 at 9:00 am
Herantis Pharma Plc ("Herantis") will publish its Financial Statements in regard to 2018 on the 28th of February 2019. The financial reporting schedule of Herantis in 2019 is as follows:
- Financial Statements bulletin in regard to 2018 on Thursday the 28th of February 2019
- Interim Report on January-June 2019 on Wednesday the 28th of August 2019
The Annual General Meeting is planned to be held on Thursday the 11th of April 2019. The Board of Directors will present a formal notice at a later stage.
The Annual Report for 2018 will be published in electronic format on the company's web site by the 20th of March 2019.
Further information:
Herantis Pharma Plc, Pekka Simula, CEO, telephone: +358 40 7300 445
Company web site:
Certified Advisor: UB Securities Ltd, telephone: +358 9 25 380 225
About Herantis Pharma Plc
Herantis Pharma Plc is an innovative drug development company focused on regenerative medicine and unmet clinical needs. Our clinical stage assets CDNF and Lymfactin® are based on globally leading scientific research in their fields. They both aim at breakthrough in the treatment of severe diseases: CDNF in neurodegenerative diseases such as Parkinson's disease; and Lymfactin® in breast cancer associated lymphedema with potential also in other lymphedemas. The shares of Herantis are listed on the First North Finland marketplace run by Nasdaq Helsinki stock exchange.
Distribution:
Nasdaq Helsinki
Main media
www.herantis.com
MENAFN1812201800703653ID1097847168
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.